Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Lysine-specific demethylase 5B (KDM5B) is overexpressed in various cancers, including breast, lung, liver, and prostate.
• Targeting KDM5B is a promising strategy for anticancer therapy, but existing inhibitors face limitations in clinical application due to toxicity and specificity issues.
• Identifying novel therapeutic agents for KDM5B is crucial for advancing cancer treatment.

Purpose of the Study:

• To investigate the potential of repurposing known antiviral agents as KDM5B inhibitors for cancer therapy.
• To evaluate the binding affinity of specific antiviral drugs to the JmjC catalytic domain of KDM5B using molecular docking.
• To explore new avenues for cancer treatment by identifying drugs with dual antiviral and anticancer activities.

Main Methods:

• Literature review on the significance of KDM5B in cancer.
• In silico molecular docking studies of selected antiviral agents (decitabine, entecavir, abacavir, penciclovir, 3-deazaneplanocin A) against the KDM5B JmjC domain.
• Analysis of binding interactions and potential inhibition mechanisms.

Main Results:

• Molecular docking revealed that antiviral agents including decitabine, entecavir, and 3-deazaneplanocin A can bind to the JmjC catalytic domain of KDM5B.
• These interactions suggest a potential for KDM5B inhibition by these repurposed drugs.
• The study identified specific binding modes and interactions that support the therapeutic potential of these agents.

Conclusions:

• Antiviral agents show promise for repurposing in cancer therapy by targeting KDM5B.
• Decitabine, entecavir, and 3-deazaneplanocin A are potential candidates for further investigation as anticancer drugs.
• Drug repurposing offers an efficient strategy to develop novel KDM5B-targeted cancer therapies with potentially improved safety profiles.